Indoline-sulfonamides compounds
    7.
    发明申请
    Indoline-sulfonamides compounds 失效
    二氢吲哚磺酰胺化合物

    公开(公告)号:US20080058386A1

    公开(公告)日:2008-03-06

    申请号:US11798079

    申请日:2007-05-10

    摘要: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

    摘要翻译: 公开了一系列二氢吲哚磺酰胺化合物。 二氢吲哚磺酰胺化合物的配方如式(I)所示。 在式(I)中,R 1是H或卤素; R 2是Ar,Ar-C(O) - ,Ar-CH 2 - ,Ar-SO 2 - ,Ar-OC( O)或R“C(O) - ,Ar是取代或未取代的C 5 -C 20芳基,环基,杂环基或杂芳基,R'和R”独立地是C 1 -C 10烷基或C 1 -C 10 烷氧基 R 3是C 5 -C 15芳基或C 1 -C 10烷基。 本发明中公开的二氢吲哚磺酰胺化合物的特征在于抑制微管蛋白聚合,并用合适的药学上可接受的载体处理癌症和其它微管蛋白聚合相关疾病。

    Indoline-sulfonamides compounds
    9.
    发明授权
    Indoline-sulfonamides compounds 失效
    二氢吲哚磺酰胺化合物

    公开(公告)号:US07741495B2

    公开(公告)日:2010-06-22

    申请号:US11798079

    申请日:2007-05-10

    IPC分类号: C07D209/44 A61K31/41

    摘要: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

    摘要翻译: 公开了一系列二氢吲哚磺酰胺化合物。 二氢吲哚磺酰胺化合物的配方如式(I)所示。 在式(I)中,R 1为H或卤素; R2是Ar,Ar-C(O) - ,Ar-CH2-,Ar-SO2-,Ar-O-C(O)或R“-C(O) - ,Ar是取代或未取代的C5- C20芳基,环基,杂环基或杂芳基,R'和R“独立地为C 1 -C 10烷基或C 1 -C 10烷氧基; 且R 3为C 5 -C 15芳基或C 1 -C 10烷基。 本发明中公开的二氢吲哚磺酰胺化合物的特征在于抑制微管蛋白聚合,并用合适的药学上可接受的载体处理癌症和其它微管蛋白聚合相关疾病。

    Z-stilbenes derivatives and the pharmaceutical composition thereof
    10.
    发明申请
    Z-stilbenes derivatives and the pharmaceutical composition thereof 失效
    Z-二苯乙烯衍生物及其药物组合物

    公开(公告)号:US20080096973A1

    公开(公告)日:2008-04-24

    申请号:US11655088

    申请日:2007-01-19

    摘要: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.

    摘要翻译: 公开了一系列具有式1所示结构的Z-二苯乙烯衍生物。在式1的结构中,X是氢,NHR或硝基,R是氢。 Y和Z独立地为氢,卤素,C 1 -C 10烷基或C 1 -C 10烷基。 烷氧基。 此外,A是氢,羟基或氨基。 本发明的化合物具有水溶性和抗肿瘤活性。 本发明的Z-二苯乙烯衍生物可以进一步包括药物载体,以形成药物组合物作为有效的抗有丝分裂剂和抗癌剂。